lithiumnefropathie lithiumnephropathy
Conditions
Interventions
Group I: stops lithium (actual dosage discontinued in three months, reduction with 1/3 every month).
Group II continues lithium in combination with amiloride.
Sponsors
does not apply
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients on chronic lithium therapy and progressive renal function loss, defined as a plasma creatinine concentration increase of at least 10 umol/l/year during at least 5 years, a correlation coefficient of 0.85 on linear regression analysis and a maximum plasma creatinine value of 200 umol/l; 2. Patients must be normotensive (if necessary, with treatment).
Exclusion criteria
Exclusion criteria: 1. Inability to give informed consent. (e.g. manic or depressiee episode, at discretion of psychiatrist); 2. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The result of combining lithium with amiloride should be reflected in a change in the course of de plasma creatinine concentration (at least cutting in half the slope of the plasma creatinine concentration) within 9 months. | — |
Contacts
Public ContactW.H. Boer
postbus 85500
Outcome results
None listed